Modern Approaches for developing bedside Rapid Diagnostics

for Viral Haemorrhagic Fever diseases

Development of diagnostic tests for Viral Haemorrhagic Fever diseases

Development of Capacity building programme in West Africa

Increase preparedness for future outbreaks

VHFModrad

Tools

VHFMoDRAD is a four-year European Collaborative Research Project, which has started in January 2019 and is part of IMI’s EBOLA+ programme that was launched in 2014 to respond to the Ebola epidemic by accelerating all aspects of vaccine development and diagnostics.

Goal

VHFMoDRAD will develop and deliver rapid and point-of-care multiplex diagnostic tool(s) that will significantly increase our capacity to handle outbreaks with Filoviruses and other viral hemorrhagic fever diseases in Africa.

Dissemination

VHFMoDRAD will also put in place a strong capacity building programme in West Africa. The project will disseminate widely all results as they become available, notably to public health bodies and non-governmental organisations (NGOs), via a strong outreach programme.

Expected outcomes

The major expected results are the development of innovative and novel diagnostic tools for VHF diseases and the reinforcement of capacity building.

WHO WE ARE

THE CONSORTIUM

13 Organisations:

0

Institutes

0

SMEs

0

Large company

0

Private Management company

0

NGO

The consortium brings together cutting-edge complementary partners, including 1 large company, 2 small and medium enterprises, one technology transfer/management private company, one NGO and 8 research institutions from 6 European Member States (Sweden, UK, France, Belgium, Denmark, Italy) and from Senegal.

WHAT WE DO

0

Work packages

0

Total Project Budget (€)

0

Years duration

VHFMoDRAD started in January 2019 and is coordinated by Folkhälsomyndigheten (the Public Health Agency of Sweden, FoHM, represented by Professor Ali Mirazimi). VHFMoDRAD has received financial contribution from Innovative Medicines Initiative 2 Joint Undertaking (IMI 2 JU) and from industrial partners, of which €1,574,000 from the large company (CEPHEID, IMI Associated Partner) and €160,000 from two SMEs (CORIS and RD-Biotech).
The project is organised into seven work packages and, over a four-year period, will focus on the development of multiplex novel, robust, highly sensitive and rapid diagnostic tests to detect VHF viruses and diseases in biosafe conditions.

OBJECTIVES

  • to develop rapid molecular and serological single/multiplex detection assays;
  • to perform preclinical validation of diagnostic tools;
  • to validate the successful diagnosis tools under field conditions;
  • to implement a strong capacity building programme in West Africa by a twining program;
  • to exploit results and to disseminate the results to public health bodies, NGOs, outbreak management teams and local hospitals in West Africa.

LATEST NEWS

Start of VHFMoDRAD project for the development of Rapid and Multiplex Point-of-Care for diagnosis of Viral Haemorrhagic Fever diseases

The project VHFMoDRAD is officially launched in Paris, France on 21st of January 2019. Coordinated by Prof. Ali Mirazimi at Public Health Agency of Sweden (Folkhälsomyndigheten), the project aims

Continue Reading
© VHFMoDRAD 2019, Website Created by FMOSys